| Brain Capillary Endothelial Cells | |
|---|---|
| Lineage | Endothelium > Brain Capillary |
| Markers | CLDN5, OCLN, CDH5, PECAM1, SLC21 (GLUT1) |
| Brain Regions | Cerebral Vasculature |
| Disease Vulnerability | Alzheimer's Disease, Vascular Cognitive Impairment, Stroke |
Brain Capillary Endothelial Cells is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brain capillary endothelial cells (BCECs) form the structural foundation of the blood-brain barrier (BBB), creating a highly specialized interface that tightly regulates the exchange of molecules between the blood and the brain parenchyma. These cells differ dramatically from peripheral endothelial cells, possessing unique features including tight junctions, minimal pinocytic activity, and polarized transporter expression. BCECs are essential for maintaining neural homeostasis, protecting the brain from pathogens and toxins, and facilitating the selective transport of nutrients required for neuronal function. In neurodegenerative diseases, BCEC dysfunction contributes to neurovascular unit breakdown, impaired clearance of toxic proteins, and reduced cerebral blood flow.
Brain capillary endothelial cells are characterized by extensive tight junctions (also called zonula occludens) that create the BBB's paracellular barrier:
Unlike peripheral capillaries, BCECs lack fenestrations (pores), preventing free passage of molecules through the endothelial cytoplasm.
BCECs exhibit minimal caveolae-mediated transcytosis, further restricting non-specific transport.
BCECs express numerous transporters that mediate selective nutrient uptake:
| Transporter | Function | Substrate |
|---|---|---|
| GLUT1 (SLC2A1) | Glucose transporter | Glucose |
| LAT1 (SLC7A5) | Large neutral amino acid transporter | Amino acids |
| CAT1 (SLC7A1) | Cationic amino acid transporter | Arginine, lysine |
| P-gp (ABCB1) | Efflux transporter | Toxins, drugs |
| BCRP (ABCG2) | Efflux transporter | Heme, drugs |
BCECs maintain the blood-brain barrier through:
BCEC dysfunction is a critical contributor to AD pathogenesis:
| Approach | Agent | Status | Mechanism |
|---|---|---|---|
| P-gp inhibition | Tariquidar | Clinical trials | Increase brain drug delivery |
| Tight junction modulators | Bradykinin analogs | Preclinical | Temporary BBB opening |
| Nanoparticle delivery | PEGylated liposomes | Clinical trials | Targeted transport |
| RAGE inhibitors | Azeliragon | Clinical trials | Reduce A-beta transport |
The study of Brain Capillary Endothelial Cells has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.